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ABSTRACT
Robinson, Sergei Alexander. M.S., Department of Neuroscience, Cell Biology and
Physiology, Wright State University, 2011. Aquaporin 4 expression and distribution
during osmotic brain edema and following chronic treatment of desipramine.

Osmotic brain edema or chronic treatment with desipramine alters brain water
permeability. In this study we investigated aquaporin 4 expression and distribution in
these two conditions. Brain edema development was induced by intraperitoneal water
injection. Blood serum osmolality decreased from 296 ± 1 mOsm to 278 ± 2 mOsm
within 15 min. Cerebral cortex water content increased from 79.8 ± 0.2 % to 81.3 ± 0.5%
during 120 min of this hyposmotic exposure. Aquaporin 4 immunostaining intensity at
the astrocytic endfeet increased in water injected animals from 2.6 ± 0.04 intensity unites
(IU) to 3.2 ± 0.21 IU, while total brain AQP4 expression remained unaltered. Chronic
treatment with desipramine showed no significant change in serum osmolality or cerebral
cortex water content. Similar to water injected animals, aquaporin 4 immunostaining
intensity in chronic desipramine animals increased at the astrocytic endfeet (2.5 ± 0.04 IU
to 3.0 ± 0.13) but total cortical AQP4 expression was again unaltered. These experiments
suggest that decreased brain water permeability caused by osmotic brain edema is not a
result of decreased AQP4 expression or localization of astroglial endfeet. However
chronic treatment with desipramine increases AQP4 immunostaining at the astrocytic
endfeet without increasing overall AQP4 expression.
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CHAPTER I
INTRODUCTION

1

The blood-brain barrier is relatively impermeable to many amino acids, peptides
and ions. Nonpolar gases, transit this structure by simple diffusion, while essential polar
and charged molecules must cross through via carrier mediated transport or channels.
The selectivity of the blood-brain barrier results from a unique endothelial cell system
that is connected through tight junctions and is free of any fenestrations. The
maintenance and regulation of the blood-brain barrier and its associated transporters
occurs through perivascular neurons and glial cells which combine with the endothelial
cell network to form the neurovascular unit.
A group of transmembrane water channel proteins called aquaporins are involved
in water transport in several organs. Aquaporin 4 is found at the astrocytic endfeet
surrounding cerebral capillaries. The localized polarity of aquaporin-4 to the astrocytic
endfeet may be a result of several adjacent proteins including syntropin and dystrophin.
The role of aquaporin 4 in water transport during pathological injuries has recently been
examined by several authors. In cellular brain edema caused by systemic hyponatremia
aquaporin 4 has been shown to be detrimental to the survival of animals. During edema
caused by a disruption of the blood brain barrier however, aquaporin-4 plays a beneficial
role in clearing excess interstitial fluid, thus increasing the chance of survival.
Regulation of aquaporin 4 occurs largely at the c-terminus by the phosphorylation of
several kinases (PKC, PKA, PKG, and CaMKII). Several drugs, altering kinase activity
have been used to attenuate brain edema.
Development of osmotic edema and the use of tricyclic antidepressants have
previously been shown to alter water permeability in the brain. Various changes in
aquaporin 4 localization have been reported during osmotic edema. In addition, the role
2

of the noradrenergic system on aquaporin 4 in the brain has not yet been studied. The
purpose of this thesis is to determine if the alteration of cerebral water permeability
caused by chronic use of antidepressants and induced osmotic brain edema is the result of
alterations of aquaporin-4 expression and cellular distribution.

3

CHAPTER II
LITERATURE REVIEW

4

1.

Blood-brain barrier and aquaporin

Blood-brain barrier
The blood-brain barrier (BBB) is a highly selective endothelial cell system that
differs from that found in the rest of the body. The BBB is relatively impermeable to
many amino acids, peptides, and ions. Some nonpolar gases such as oxygen and carbon
dioxide can be transported freely across membrane while larger polar molecules such as
glucose and amino acids require carrier mediated transport [1]. Any charged substances
such as ions (sodium, potassium, chloride and bicarbonate) must cross the BBB by active
transport [1, 2]. Endothelial cells that compose the barrier are free of fenestrations and
are attached to each other by an extensive system of junctional complexes including tight
junctions and adherens junctions [3, 4]. The tight junctions associated with BBB include
three main integral proteins; claudins [5], occludens [6] and junctional adhesion
molecules [7]. The regulation and possibly even the development of these tight junctions
are thought to be controlled largely by astrocytes [4, 8-10]. The surface of blood vessels
in the brain are surrounded by a close network of astrocytic endfeet [9]. These endfeet
are suggested to be involved in the maintenance and repair of the BBB. In addition to
glial cells, perivascular neurons (surrounding blood vessels) are involved in maintaining
the BBB. The combination of perivascular neurons, astroglia and endothelial cells are
collectively known as the “neurovascular unit” [11, 12]. All components play an
essential role in the selectivity, maintenance, and regulation of the BBB.
BBB function is influenced by various neurotransmitter systems. The water
permeability of the BBB may be under the control of the noradrenergic system. The
stimulation of the locus coeruleus increases the water permeability[13]. In contrast,
5

blocking α-adrenergic receptors produces opposite results [13, 14]. Noradrenergic
neurons, however rarely directly interact with the brain vascular walls but instead
innervate the vasculature through the glia [15]. Neurotransmitters (glutamate,
norepinephrine, dopamine and acetylcholine) are also thought to play a role in cerebral
blood flow by the constriction or dilation of blood vessels. Glutamate has been suggested
to produce indirect vasodilatation of the smooth muscle cells in the cerebral vasculature
by stimulating cells which surround the vasculature to release vasoactive factors [16, 17].
Stimulation of noradrenergic neurons causes vasoconstriction and a reduction in cerebral
blood flow [13]. Studies regarding serotonin involvement in cerebral blood flow indicate
serotonin has a strong vasoconstriction effect, but also during some conditions this
neurotransmitter may have a vasodilator effect [16]. Dopaminergic neurons cause
vasoconstriction in both cortical slice preparations [18] and in situ [19]. Acetylcholine
has been suggested to play a role in vasodilatation causing an increase in cerebral blood
flow as was tested by stimulation of the basal forebrain, a major source of cholinergic
perivascular innervation [20].
Aquaporins
Water permeability across the blood brain barrier has been studied extensively.
Previously it was thought that water transport occurred solely by slowly dissolving
through phospholipid bilayer and not by pores or slits [21, 22]. In other studies however,
it has been suggested that in addition to diffusion though the plasma membrane water
may move though small 12 Å pores within the endothelial cells [23]. Water passes
through cells faster than expected via simple diffusion. It is suggested that aquaporins
(water channels) evolved to actively regulate rapid osmotic diffusion across the plasma
6

membrane in several tissues [24-26]. To date there are three major groupings of the
aquaporin gene family: aquaglyceroporins, aquaporins and unorthodox aquaporins [27].
Aquaglyceroporins are responsible for movement of water, glycerol and other nonpolar
solutes such as urea. The aquaporin (AQP) group is responsible for movement of water
only, while some unorthodox aquaporins are able to transfer ions as well as water.
Currently four aquaglyceroporins (AQP3, AQP7, AQP9 and AQP10) five aquaporins
(AQP0, AQP1, AQP2, AQP4 and AQP5) and four unorthodox aquaporins (AQP6,
AQP8, AQP11 and AQP12) have been identified [26, 28, 29]. The entire aquaporin
family of proteins can facilitate bidirectional transport and are found in tissues involving
of water flux (Figure 1). Despite their different specificities all three groups have a
similar structure with roughly 300 amino acids and six transmembrane domains (Figure
2) with cytoplasmic C- and N- termini [30, 31].

7

Figure 1. Location of aquaporin isoforms in mammals (from Zelenina et al.) [32].
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Figure 2. Structure of aquaporin having cytoplasmic N- and C-termini [31].
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Aquaporin 4
Of the three aquaporins found in the brain (AQP1, 4, 9) [33-36], AQP4 will be the
focus of this thesis due to its relationship with the BBB and expression in astrocytes.
Aquaporin 4, previously known as mercurial insensitive water channel (MIWC) [37, 38],
is located on the plasma membrane of cells and is responsible for bidirectional flow of
water in many tissues, including the brain [39-41]. Outside the brain, AQP4 is found in
the kidney (principle cells), sarcolemma membrane of skeletal muscle myocytes, parietal
cells of the stomach (basolateral aspect), salivary gland, lacrimal gland, colon (villus
epithelium), trachea bronchi, iris, ciliary body, and neural cell layers in the retina [37,
38]. In the brain AQP4 is predominantly found in astrocytes and ependymal cells,
although some suggest AQP4 also may be present in endothelial cells [42], neurons, and
Purkinje cells of the cerebellum [43].
The majority of AQP4 in the brain is polarized to astrocytic endfeet surrounding
capillaries, areas lining the ventricles, and on the glia limitans [38, 44-52]. In areas where
systemic osmotic regulatory control is necessary such as the supraoptic nucleus and
subfornical organ, AQP4 is less polarized and is instead distributed along the entire
astrocytic membrane [45]. While some have suggested AQP4 may have a role in
osmoregulation [45], studies using AQP4 knockouts show no difference in serum
osmolality indicating little evidence for AQP4’s role as an osmoregulatory effector [53].
Freeze fracture studies shows that AQP4 forms intramembranous square arrays
termed orthogonal array of particles (OAP) [54]. Interestingly these square arrays were
seen at astrocytic endfeet prior to the discovery of AQP4 and its role in water transport
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[55-57]. Immunogold analysis has confirmed that the square arrays are complexes of
AQP4 [58]. Early studies suggest that the assemblies disappear during periods of low
oxygen [56].
Aquaporin 4 is relatively insensitive to mercury unlike similarly structured AQP1
[59]. A lack of cysteine at sites G94 and A210 in AQP4 is thought to be responsible for
this phenomenon since these are the corresponding mercury inhibitory sites for AQP1.
Substitution of cysteine for alanine at these locations in AQP4 retains mercury
insensitivity suggesting that AQP1 and AQP4 structures are less homologous than
initially assumed [43]. Creating cysteine substitutions, however at residues 70-73 and
189 results in mercury sensitivity [59]. These findings suggest that the lack of cysteines
near the aqueous pore (NPA, Figure 2), and not at homologous residues found in AQP1,
is responsible for AQP4 mercury resistance [59].
In astrocytes AQP4 forms protein complexes with other channels and proteins.
Knockouts of α-syntropin decrease the polarity of AQP4 localization, showing a 90%
decrease at astrocytic endfeet and increased immunostaining elsewhere. The loss of
polarity is attributed to AQP4 association with α-syntropin since the total AQP4 protein
expression remains unchanged. The α-syntropin knockout shows no effect on AQP4
localization in the kidney, brain ependymal cells and supraoptic nucleus [42]. Similarly,
dystrophin-null mice show a drastic decrease in AQP4 localization at the endfeet while
total brain AQP4 expression is unaltered. These results suggest that AQP4 forms a
complex with dystrophin with the use of an adaptor protein (α-syntropin) [41, 60, 61].
Interestingly, the polarity of AQP4 also is strongly dependent on agrin (heparin sulfate
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binding proteoglycan) suggesting that the entire α-syntropin, dystroglycan, agrin complex
must be present in order to retain AQP4 polarity [52].
Kir4.1channels also have been shown to colocalize strongly with AQP4 at
astrocytic endfeet [61] and in rat retina cells [62]. The colocalization of Kir4.1 and
AQP4 observed at the electron microscopy level of magnification suggests that AQP4mediated osmotic flux may be associated with potassium siphoning [62]. In α-syntropin
null mice Kir4.1 immunoreactivity is only modestly reduced suggesting that Kir4.1 and
AQP4 may not be bound to one another but are nonetheless adjacent. Additionally, delay
in potassium clearance is seen in α-syntropin null mice further suggesting a strong
correlation of AQP4 and inward siphoning of potassium using the Kir4.1 channel [63].
Recently interactions between aquaporins and Na+/K+ ATPase have been studied. Strong
evidence that AQP4 can assemble with the metabotropic glutamate receptor 5 (mGluR5)
and Na+/K+ ATPase lends additional support for AQP4’s involvement in potassium
homeostasis and glutamate signaling as well as water transport [64].
2.

Edema and Aquaporin

Edema
Brain edema is caused by an abnormal amount of fluid resulting in an increase of
brain tissue volume. There are two main types of brain edema, cytotoxic and vasogenic
[65-67]. Cytotoxic brain edema is caused by water moving via an osmotic gradient,
usually caused by a cellular metabolic dysfunction causing either intracellular
hyperosmolarity or extracellular hyposmolarity [67]. During cytotoxic edema the BBB
may remain fully intact. In vasogenic edema however the BBB is disrupted. This may
14

occur from brain trauma, tumors or strokes [65]. Several animal models of vasogenic
edema have been employed for research including fluid percussion, direct cortical
contusion (either unilateral or bilateral) and focal freeze injury. The disruption of the
BBB in these situations causes an increase in vascular permeability with an increase of
fluid in the extracellular space due to extravasation of blood plasma. Vasogenic and
cytotoxic brain edema may occur simultaneously in pathological conditions [48-50, 68].
Systemic hyponatremia may cause cytotoxic brain edema. Decreased osmolarity
within the lumen of the capillary causes an increased osmotic drive of water through
endothelial cell membranes. Once the hyposmotic solution crosses the endothelial cells,
the extracellular space becomes hypotonic and water moves into the brain parenchymal
cells. Thus during cytotoxic edema, astrocytic endfeet processes surrounding capillaries
begin to swell. Transmission electron microscopy at the BBB shows an increase in the
astrocytic end feet processes surrounding the brain capillaries from 0.73 +/- 0.10 µm2 to
5.78 +/- µm 2 [69]. Osmotic brain edema is a common model used to induce cytotoxic
brain edema in the laboratory. During osmotic brain edema, a hyposmotic solution is
injected intraperitoneally (IP) and is absorbed through the mesenteric vasculature. This
in turn causes the systemic hyponatremia throughout the organism resulting in cellular
swelling in the brain [70]. Sodium and chloride efflux from the brain is greatest during
the first thirty min of acute hyponatremia while a significant decrease in potassium is
observed at three hours [71].
During the initial stages of systemic hyponatremia, the brain may play a
protective role by decreasing water permeability and through the reduction of total brain
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osmolytes [70]. The loss of electrolytes in the brain is another symptom of
hyponatremia.
Animal models of stroke also cause cytotoxic edema [69]. However, in an
ischemic brain both cytotoxic and vasogenic edema can be present. Initially cytotoxic
brain edema develops following cellular energy decrease due to the acute loss of glucose
and oxygen. After time, blood-brain barrier injury may lead to vasogenic edema[65].
Aquaporin 4 and edema
AQP4 water permeability has been implicated in brain edema formation and
resolution. The role of AQP4 in cytotoxic and vasogenic brain edema has been explored
by measuring AQP4 expression and localization.
Cytotoxic brain edema
Studies suggest that AQP4 protein expression rises significantly during cytotoxic
brain edema but mRNA remains unchanged [44, 46, 47, 72]. During prolonged osmotic
brain edema induced by IP water injection, a significant increase in AQP4 expression in
whole brain to 164% and 153% of control values has been observed 4 and 48 hour after
water injection respectively [44]. Cerebellar samples also showed a similar increase in
expression when compared to control animals. Analysis of AQP4 mRNA expression was
used to evaluate the effect of water intoxication at the transcriptional level. No
significant increase was seen in AQP4 mRNA in either the whole brain or cerebellum
after 4 hours of systemic hyponatremia [44]. Similar results showing an increase in
AQP4 protein expression were seen during a transient middle cerebral occlusion, a model
of pathology which causes both cytotoxic and vasogenic edema [65, 73].
16

Cytotoxic brain edema also can be a consequence of acute liver disease [74, 75].
Increased expression of AQP4 is seen during cerebral edema induced by acute liver
disease brought on by intraperitoneal injection of galactosamine, lipopolysaccharide and
intravenous injection of ammonium-acetate [35]. An increase of brain water content from
80.1% to 80.8% was correlated with an increase of AQP4 protein expression of 1.64 fold
compared to control [35]. Similarly to previous experiments with cytotoxic edema
induced by systemic hyposmotic hyponatremia [44], no change in AQP4 mRNA
expression was observed. In vitro studies with primary astrocytes also have
demonstrated increased ammonia levels alone can enhance AQP4 protein expression [76,
77].
During osmotic brain edema water entering brain parenchyma must first cross the
endothelial cell membrane before reaching the astrocytic cell membrane. If the passage
of water across the endothelial cell membrane was the rate-limiting factor,
overexpressing AQP4 would cause no difference in the rate of water transport.
Transgenic mice overexpressing AQP4 have been used to study the rate-limiting factors
governing the development and resolution of cytotoxic edema. These animals showed a
2.3 fold increase in AQP4 protein expression when compared to control mice [47]. The
induction of osmotic brain edema caused an increase in brain swelling that was recorded
within ten min of IP water injection. Intracranial pressure ten minutes after injection was
20 ± 2 mmHg in transgenic mice, 14 ± 2 mmHg in control mice and 9.8 ± 2 mmHg in
AQP4 knockouts. These data suggests that water transport into glial cells via AQP4 must
be a rate-limiting factor for edema development in this animal model [47].
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Microscopy also has shed light on AQP4 involvement during cytotoxic brain
edema. Increased AQP4 immunoreactivity of the hippocampus was observed after 90
min of water intoxication [46]. Immunostaining of AQP4 was more widespread and
diffused in the hippocampal region than in control animals. Additionally, staining around
vessels was spotty and less polarized, making vessels appear longer and thicker during
edema [46]. Similar AQP4 immunoreactivity has been seen in spontaneously
hypertensive rats as in rats with cytotoxic brain edema [72]. Consistently, induction of
brain edema with an intact blood-brain barrier has showed an increase in immunostaining
and immunoblotting of AQP4 protein with little change to mRNA levels.
Some authors suggest that immunohistochemistry provides a poor evaluation for
analysis of AQP4 distribution. Vajda et al. [44] suggest that light and electron
microscopy cannot be used to determine AQP4 redistribution on the plasma membrane
facing the capillaries, but freeze fracturing must be done because it is uncertain if AQP4
redistribution occurs under standard microscopy [44, 54].
In a related study, animals with the α-syntropin knockout have decreased polarity
of AQP4 at the perivascular membrane of glial cells by as much as 90% and show a delay
in edema formation during hyponatremia [42]. The α-syntropin knockout seems to only
be associated with AQP4 found on astrocytic membrane since total brain AQP4 is
unaffected. Dystrophin null mice produced a similar mislocalization of AQP4 and a
delayed onset of osmotic brain edema [60]. These results suggest that AQP4 localization
and polarization are crucial for osmotic edema development and thus, could be a target
for drugs to delay onset of edema [42].
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Aquaporin 4 knockout and cytotoxic edema
Knockout studies involving both cytotoxic and vasogenic brain edema have shed
light on AQP4’s role for brain volume regulation. In this genetic model, little or no
change in tissue, organ development, neuromuscular function, or survival of mice has
been shown [53]. Additionally, expression of other aquaporins such as 1, 2, 3 and 5 were
not affected and no change in BBB integrity or morphology has been seen with AQP4
gene deletion [78]. No tight junction misformation, myelination, increased intercranial
pressure or alterations in vascular anatomy were noted by several sources [69, 78-80].
Interestingly though, one study has shown evidence for decreased GFAP expression and
open cerebral endothelial tight junctions in AQP4 knockout animals [33].
During cytotoxic brain edema AQP4 may play a detrimental role for animal
survival while during vasogenic edema, AQP4 may be involved in removing excess fluid
from the brain and thereby increasing the chances of survival [69]. Compared to
wildtype mice, knockouts show a decrease of swelling in the astrocytic feet processes and
water content in the brain after 30 min of acute water intoxication [69]. Additionally,
AQP4 knockout animals show less of an increase in intracranial pressure during osmotic
brain edema when compared to wild type mice [81]. Null mice also showed a delay in
the increase of intracranial pressure. This delay could correlate with decreased water
accumulation caused by lowered BBB osmotic water permeability in the AQP4 null
animals.
In an ischemic stroke model of cytotoxic brain edema using permanent middle
cerebral artery occlusion, AQP4-deficient mice had decreased hemispheric enlargements
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(35%) and infarct volume [69]. Increased chance of survival and improved neurological
scores also were observed in AQP4 knockout mice [69]. In cultured astrocytes similar
results were seen during cell swelling. In astrocytes containing AQP4, cell volume was
significantly higher than for AQP4 knockout mice during oxygen and glucosedeprivation induced swelling. Reoxygenation after six hours of oxygen and glucose
treatment however, returned the cell volume back to control levels two days faster in
AQP4 wildtype mice [39]. These data suggests that AQP4 is a key player for both influx
and efflux of water in astrocytes.
In pneumococcal meningitis, where cytotoxic edema is thought to predominate
over vasogenic edema, AQP4 also plays a detrimental role. Wildtype mice showed a
fivefold increase in water permeability in the brain causing elevation of both intracranial
pressure and water content. AQP4 null mice showed signs of infection but remarkably
little change in intracranial pressure during meningitis [79].
In summary, during systemic hyponatremia the accumulation of brain water is
significantly decreased in AQP4 knockout mice. AQP4 may play a pivotal role in
osmotic permeability into brain parenchyma and its deletion has been shown to decrease
the rate of development of cytotoxic brain edema.
Vasogenic brain edema
Various changes in AQP4 expression have been reported during vasogenic brain
edema. However, it is important to note that during vasogenic brain edema, cytotoxic
brain edema also may be present.
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Several cortical impact models have reported AQP4 protein and mRNA changes
during the evolving edema. Both a decrease [48, 49, 68] and increase [49, 50, 82] in
AQP4 immunoreactivity has been observed on the damaged side of the brain.
In a controlled cortical impact model, where one hemisphere of the brain is
damaged, AQP4 protein and mRNA expression decreased significantly one day after the
cortical contusion injury in the ipsilateral damaged hemisphere. [48, 68]. In the
contralateral hemisphere however, there was no change in AQP4 protein or mRNA
expression at this time point [48, 68], while a significant decrease in AQP4 protein was
observed 48 hours after injury [68]. Confocal microscopy findings were consistent with
the results of lowered AQP4 protein expression at the contusion core 24 hours after
injury. Semi-quantitative immunohistochemistry using confocal microscopy showed a
decrease in AQP4 immunoreactivity in the brain following a controlled cortical contusion
injury at the impact site; however, an increase in AQP4 immunoreactivity was seen in
surrounding areas [49]. A possible functional explanation for the immunoreactivity
finding is that AQP4 in the surrounding contused area is up-regulated to buffer the
increase in interstitial fluid.
Other studies with opposite findings have been published regarding AQP4 protein
expression in cortical impact injury. One study showed an increase in both AQP4
expression and water content on the injured side of the brain [82]. Additionally in a
bilateral controlled cortical model, AQP4 protein expression was significantly increased
in the area immediately surrounding the contusion after 72 hours but not after 24 hours.
AQP4 expression was not measured at the core of the contusion [50]. The differences in
these finding may be a result of differences in the location of tissue sampled relative to
21

the contused area. Additionally the extent of injury and time of tissue extraction after
injury may be important. Previous reports suggest that maximal brain edema following
cortical contusion injury appears between 24 and 72 hours [83, 84]. During this time,
AQP4 expression may be fluctuating, thus leading to inconsistent finding between labs.
AQP4 protein expression is altered by several drugs which decrease formation of
brain edema. In both a middle cerebral artery occlusion and cortical contusion injury
animals receiving SR49059 (V1a vasopressin antagonist) treatment immediately after
injury showed a significant decrease in both AQP4 protein expression and water content
compared untreated injured animals [73, 82]. In the bilateral contusion model, a similar
decrease of AQP4 protein expression lessened the brain edema in progesterone-treated
animals compared to untreated injured animals [50].
In the cortical contusion injury model, injection of sulforaphane, a possible
anticancer drug, six hours after injury caused a smaller decrease in AQP4
immunostaining at the contusion core compared to injury only animals. Furthermore
AQP4 immunostaining significantly increased in areas surrounding the contusion 24 and
72 hours after injury in sulforaphane treated animals. This could suggest a possible use of
sulforaphane to increase AQP4 expression during vasogenic edema. To test this theory
brain water content was measured 24 hours and 72 hours after brain injury. Animals that
were injected with sulforaphane after injury showed a significant 0.64% decrease in total
brain water content only three days after injury compared to non-sulforaphane treated
animals [49].
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Additional publications reported results using a cerebral artery occlusion to model
vasogenic edema. In immature and juvenile rats with a permanent right carotid artery
occlusion and induced hypoxic environment, AQP4 immunostaining but, not AQP4
protein expression, was decreased 1 hour and 24 hours after injury [51]. This difference
in relative change in AQP4 expression using immunohistochemical and western blot
techniques suggests that changes in immunostaining may not be a result of changes in
protein expression, but rather caused by altered protein conformation since there was no
change in total AQP4 protein expression. In a transient (30 min) middle cerebral artery
occlusion model however, an increase in AQP4 expression was observed one hour after
ischemia (30 min after reperfusion) in the ipsilateral cortex [85].
Several other drugs also have been used in an attempt to reduce vasogenic edema
after transient artery occlusion. Low dose thrombin injection prior to ischemia caused an
increase in AQP4 expression (both immunostaining and immunoblotting) compared to
untreated ischemic mice only [85]. Immunohistological results suggest that the increase
in protein expression is localized at the perivascular endfeet of glial cells. Brain water
content increase also was lessened by thrombin treatment. Thrombin treatment suggests
a protective role in vasogenic brain edema with increased expression of AQP4 in the
ipsilateral ischemic hemisphere; however, thrombin treatment prior to stroke did not
prevent early disruption of the BBB. Taken together thrombin treatment does not reduce
edema by altering the BBB but by promoting water clearance from the extracellular
space. In this study it is important to note that the increase in AQP4 expression did not
worsen edema [85] .
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An agonist for adrenergic and imidazoline receptors, agmatine, has been shown to
decrease both brain edema volume and water content after transient middle cerebral
artery occlusion independent of AQP4 expression [86]. Aquaporin 4 immunoblotting
was not significantly different between control and treatment groups. AQP1 expression
however was limited by agmatine suggesting that the decrease in brain edema was caused
by agmatine’s role in down regulating AQP1 expression.
In summary, AQP4’s involvement during vasogenic edema may be different
during arterial occlusion and cortical impact injuries. AQP4 expression and
immunoreactivity changes are altered with vasogenic edema. Studies using agents to
either increase or decrease AQP4 expression have shown these treatments decrease
intracranial pressure and edema volume. Knockout studies however, provide additional
insight in AQP4 involvement in developing vasogenic edema.
Aquaporin 4 knockout and vasogenic brain edema
AQP4 knockout studies have played an important role in determining AQP4
involvement in vasogenic brain edema. Overall, AQP4 knockout animals display higher
intracranial pressures, edema volume, and worsened neurological scores after induced
vasogenic edema.
Intracerebral fluid infusion (IFI), focal cortical freeze injury (FCI) and tumor
(melanoma) cell implantation (TCI) demonstrated higher intracranial pressure (ICP) in
AQP4 knockout mice compared with wildtype after brain injury [87]. Total water content
also increased more in knockout animals compared to injured wildtype animals following
the intracerebral fluid infusion and focal cortical freeze injury models. In the tumor cell
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implantation model AQP4 null mice showed greater neurological deterioration. In
addition, neurological scores decreased in all knockout animals compared to wildtype
animals within the assigned group. Results are summarized in Table 1.
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Table 1. Three vasogenic models performed on wild type and aquaporin 4 knockout
mice from results of Papadopoulos et al. 2004. Data are presented as mean ± SEM.
Intracerebral fluid infusion (IFI), focal cortical freeze injury (FCI) and tumor cell
implantation (TCI) were investigated.
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Model

IFI
FCI
TCI
Uninjured

AQP4 Knockout
ICP (cmH2O)
% Brain
Water
52 ± 6
81.2 ± 0.1
22 ± 4
80.9 ± 0.1
39 ± -5
NA
NA
70.2 ± 0.3
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Wildtype
ICP (cmH2O)
% Brain
Water
26 ± 3
80.4 ± 0.1
9±1
79.4 ± 0.1
19 ± 4
NA
NA
78.6 ± 0.2

The same lab investigated focal vasogenic edema induced by a staphylococcal
brain abscess. The brain abscess size was similar in wildtype and AQP4 knockout mice
and intracranial pressure and water content were elevated during edema in both groups.
However, the AQP4 null mice showed a significant increase in both intracranial pressure
and water content compared to controls [88]. Additionally AQP4 wildtype mice with
brain abscess showed a significant increase in AQP4 immunostaining around the focal
edema when compared to controls. Thus, AQP4 may provide a similar protective role in
bacterial abscess as in a tumor-induced vasogenic edema.
In summary, AQP4 deletion is detrimental during vasogenic edema caused by
focal freeze injury, intraparenchymal injection, and focal tumor/bacterial induction.
These results suggest that AQP4 plays a role in transporting water from the brain
parenchyma to intraventricular and subarachnoid compartments as a protective survival
mechanism.
3.

Regulation of aquaporin 4
Ontogeny of AQP4 expression differs among species. In rodents, AQP4 protein

expression develops in the brain just after birth while in birds AQP4 expression can be
seen prenatally [43, 89, 90]. In the rat cerebellum, AQP4 protein expression is 25% of
that in adults after 14 days postnatal [90]. A 9 day chick embryo already shows high
levels of AQP4 immunoreactivity surrounding immature tight junctions of endothelial
cells, suggesting an important role in BBB integrity [89]. Although there is strong
evidence of long-term regulatory function of AQP4 development, the focus of this thesis
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will center on treatments which affect the regulatory mechanism of the water channel in
adult rats.
As expected, the water permeability of cultured astrocytes containing AQP4 is
significantly greater than that of cells without AQP4 [91, 92]. Several studies shed light
on AQP4 regulation and its involvement in swelling at a cellular level. Increased
ammonia levels alone can increase AQP4 expression in astrocytes in vitro [76, 77].
Cultured astrocytes showed no volume change within 11 hours of ammonia treatment but
increased by 32% and 76% at 12 and 18 hours, respectively [77]. AQP4 expression also
remained steady and increased only after 10 hours. AQP4 expression and cell volume
showed a strong correlation (r=0.95) during the 12-48 hour treatment periods. These
results suggest that AQP4 protein expression is time dependent in cells treated with
ammonia.
When oocytes express AQP4, a 15-fold increase in water permeability during
hyperosmotic treatment is observed [93]. Oocytes coexpressing AQP4 and V1αR
(arginine vasopressin receptor 1A) showed a decrease in water permeability during
vasopressin exposure [93]. Thus an association between AQP4 and V1αR may regulate
water permeability change in response to vasopressin. A 65% reduction in capacitive
currents were observed in oocytes containing AQP4/ V1αR during vasopressin exposure
suggesting that the change in water permeability was caused by internalization of AQP4.
Hormones also play a role in regulation of AQP4 expression. Treatment with
testosterone, but not 17β-estradiol or dexamethasone (synthetic steroid) has been shown
to increase AQP4 protein and mRNA expression in cultured astrocytes [94].
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In transgenic mice, overexpression of endothelin-1 (potent vasoconstrictor)
induces AQP4 protein expression causing an increase in water content in the brain after
induction of osmotic brain edema [46]. However treatment with OPC-31260 (vasopressin
V2 receptor antagonist) reduced the effects of osmotic brain edema. Additionally after
treatment with OPC-31260, AQP4 immunoreactivity and protein expression was
diminished at the astrocytic endfeet suggesting a role of V2 receptor as a mediator of
AQP4 during edema [46].
Aquaporin 4 and p38mitogen-activated protein kinase (MAPK)
Mannitol treatment causes an increase in AQP4 expression in vivo and in vitro
and was used to determine the role of MAPK inhibition on AQP4 expression [24]. In
cultured rat astrocytes an increase in AQP4 mRNA expression was observed for 12 hours
after treatment. AQP4 mRNA levels returned to normal after 24 hours. AQP4 protein
expression increased within an hour and then remained constant over a period 48 hours.
This suggests transcriptional and post-transcriptional factors may influence AQP4 protein
expression. A p38 MAPK inhibitor reduced expression of AQP4 protein and mRNA in
vitro. The reduction of AQP4 expression suggests that regulation of AQP4 is partly
dependent on the p38 MAPK pathway. Phosphorylation and activation of p38 MAPK
was observed during hyperosmotic stress in cultured astrocytes [24].
Aquaporin 4 and protein kinase C (PKC)
AQP4 protein and mRNA expression also may be regulated by PKC in cultured
astrocytes [94-96]. Activation of PKC by tetradecanylphorbol acetate (TPA) causes a
decrease in both AQP4 protein and mRNA expression while pretreatment with PKC
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inhibitors (H7 and chelerythrine) attenuates the effects of TPA [95]. Additionally, PKC
activation using TPA decreased the heightened AQP4 expression that is caused by
testosterone [94].
Studies using oocytes [93, 97] and epithelial cells also suggest that AQP4
involvement in water permeability is regulated by PKC. In oocytes, PKC activators
(phorbol 12, 13-dibutyrate and phorbol 12-myristate 13-acetate PMA) decreased AQP4
activity and reduced the rate of swelling in a hyposmotic solution [93, 97]. Furthermore
increased phosphorylation of AQP4 following PMA treatment suggests regulation of
AQP4 is controlled by protein phosphorylation [97]. Additional electron microscopy and
immunocytochemistry examination suggests that activation of PKC caused AQP4
internalization in oocytes [93, 98]. In cultured kidney epithelial cells AQP4
phosphorylation at Ser180 by PKC activation is thought to decrease AQP4 permeability.
No AQP4 internalization or delocalization was observed suggesting that in this case
decreased AQP4 permeability is directly altered by phosphorylation [28].
Since PKC has been shown to regulate AQP4 expression [93-95, 97], PKC
activators have been used to control the onset of brain edema in two pathological models
[99, 100]. In one study, animals treated with phorbol ester (PKC activator) 30 in after
contusion showed decreased brain water content [99]. In a separate study in which
edema was induced via middle cerebral artery occlusion, AQP4 expression was decreased
in the ischemic area following PKC activation PMA treatment [73, 100, 101].
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Aquaporin 4 and protein kinase CK2
Protein kinase CK2 phosphorylation at the c-terminus of AQP4 has been
proposed as a signal for trafficking the protein to the plasma membrane [102, 103]. In
cultured mouse astrocytes, AQP4 is constitutively phosphorylated by protein kinase CK2
at multiple sites on the c-terminal domain [102]. Disrupting phosphorylation by CK2
inhibitors or amino acid substitution of CK2 binding sites (Ser276, Ser285, Thr289 and
Ser316) causes AQP4 accumulation by the Golgi apparatus [102]. Thus, the
phosphorylation of AQP4 by CK2 is suggested to be necessary at the Golgi apparatus or
endoplasmic reticulum prior to exiting the Golgi.
In epithelial MDCK cells expressing AQP4, phosphorylation via the CK2dependent pathway also thought to play a role for the protein degradation signaling
pathway [103]. The phosphorylation of Ser276 leads to increased interaction of a
lysosomal marker suggesting regulation of CK2 is used to traffic the protein to lysosomes
[103]. Thus the CK2 pathway may provide a regulatory means of cell surface expression
of AQP4.
Aquaporin 4 and protein kinase A (PKA)
In cultured human gastric cells, histamine treatment causes AQP4
phosphorylation and internalization followed by storage in late endosomes [104]. Once
histamine is removed, AQP4 relocates to the plasma membrane. A threefold increase in
PKA and PKC activity is seen during histamine treatment [104]. Inhibition of PKA but
not PKC reduced AQP4 phosphorylation after histamine treatment. Inhibition of PKA
however did not prevent internalization, suggesting that AQP4 phosphorylation occurs
after internalization. Thus, AQP4 phosphorylation via PKA inhibits degradation after
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internalization. By this process AQP4 is stored in a vesicular compartment and is readily
available for recycling to the plasma membrane.
Aquaporin 4 and protein kinase G (PKG)
In astrocyte cell cultures, glutamate has been shown to increase water
permeability possibly as a result of activation of group I metabotropic glutamate
receptors (mGluR) [105]. The group 1 mGluR agonist, DHPG, caused an increase in
water permeability of astrocytes containing AQP4 and an intracellular calcium response,
while an NMDA receptor agonist showed no effect. Additionally increased water
permeability caused by DHPG was abolished after adding the PKG inhibitor (H-89).
Taken together, the increase in astrocyte water permeability is calcium dependent and
may be mediated by PKG phosphorylation of AQP4 [105].
Aquaporin 4 and calmodulin-dependent protein kinase II (CaMKII)
Cultured astrocytes containing AQP4 show an increase in water permeability
upon lead intoxication but no effect of lead is seen in cultured astrocytes that are AQP4
deficient [92]. Introduction of a CaMKII inhibitor (KN-62), but not PKC inhibitor
(bisindolylmaleimide), attenuated the effect of lead on water permeability [92]. When a
potential CaMKII phosphorylation site, Ser111 was mutated, KN-62 had no effect on the
lead-induced increase in water permeability. The finding using KN-62 suggests that lead
may activate CaMKII to phosphorylate AQP4 at Ser111 resulting in increased water
permeability of cultured astrocytes.
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4.

Blood-brain barrier water permeability

Blood-brain barrier water permeability is altered during osmotic brain edema and
treatment with tricyclic antidepressants [70, 106].
Osmotic brain edema
Osmotic brain edema is a common model of cytotoxic brain edema. Water is
injected into the peritoneal cavity which induces system hyponatremia. Brain water
content, water permeability, and cerebral blood flow was studied during two hours of
osmotic brain edema induced by this treatment [70]. Brain water content increased in the
cerebral gray and white matter after two hours of edema. Additionally, water
permeability and blood flow were decreased one and two hours after treatment at which
point swelling of the astrocytic endfeet was observed [107]. In summary, data suggest an
increased resistance to osmotic water flux after osmotically induced cerebral brain edema
[70].
Tricyclic antidepressants (TCA)
TCA are often used to treat depression mainly by increasing the levels of
norepinephrine and serotonin in the brain. The general mechanism of TCA action
involves downregulating norepinephrine and serotonin transporters located on the
presynaptic terminal of neurons [108]. These selective transporters are responsible for
reuptake of neurotransmitter after it is released into the synaptic cleft. In addition, chronic
use of TCA has been shown to downregulate adrenoreceptors on the post synaptic neuron
[109, 110]. The combination of the inhibition of selective transporters and
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adrenoreceptors allow TCA to be used as agents to determine the role of noradrenergic
systems in the brain.
Several studies suggest a role of the noradrenergic system for regulating brain
capillary permeability [13, 111, 112]. To investigate the regulatory function of the
noradrenergic system, TCAs were administered to animals and cerebral capillary
permeability was measured. Acute treatment of several drugs in this class (doxepin,
amitriptyline, imipramine, nortriptyline, desipramine, and protriptyline) were
administered and cerebral capillary permeability was measured five minutes later. TCA
administration caused a significant increase in cerebral capillary permeability [106].
Animals treated with amitriptyline (AMI) daily for two weeks had a significant increase
in capillary permeability following this chronic treatment. The increase in permeability
was significantly higher in the chronic treatment group compared to the acutely treated
animals [113]. These studies show that TCA treatment has a potent effect on the
permeability of brain vasculature, suggesting a strong noradrenergic regulatory
involvement in AQP4 function.
5.

Summary

A change in cerebral capillary water permeability occurs during osmotic brain edema
and chronic treatment of tricyclic antidepressants. The change in water permeability
during these two models may result from a change in AQP4 expression and distribution
at the astrocytic endfeet. Alterations in AQP4 expression and distribution may be a result
of changes in levels of neurotransmitters and phosphorylation of serine residues on the c-
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terminus of AQP4. Our goal of this thesis is to determine AQP4 expression and
distribution during two models shown to alter brain capillary water permeability.
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CHAPTER III
HYPOTHESIS AND SPECIFIC AIMS
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This research is designed to address the question of whether or not aquaporin 4
expression and distribution is altered by two treatments that are known to change water
permeability in the brain. Our hypothesis is that regulation of aquaporin 4
localization and expression controls physiological water permeability at the blood
brain barrier.
Specific Aims
1) Observe AQP4 expression and distribution in animals undergoing osmotic brain
edema.
2) Observe AQP4 expression and distribution in animals undergoing chronic
desipramine treatment.
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CHAPTER IV
GENERAL METHODS
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This study was approved by the Laboratory Animal Care and Utilization Committee
of Wright State University and conformed to the Guide for the Care and Use of
Laboratory Animals. Twenty-eight adult male Sprague Dawley rats between 168-291
grams were used for the study. Animals were housed at the Laboratory Animal Care
facilities at Wright State University. All surgical procedures and analyses were
performed at Cox Institute in Kettering Ohio.
Animal preparation and surgical procedures
Modified methods from Olson et al were used [70]. Animals were exposed to 5%
isofluorane in a 5-liter container. After anesthesia was induced, the animal was
transported to an operating table and a face mask (Harvard Apparatus) was fitted flowing
2% isofluorane mixture in medical-grade air. Anesthesia was monitored and altered if
needed to ensure proper surgical anesthesia levels. A rectal probe and a 24 gauge
femoral arterial catheter with a heparin filled polyethylene tube were inserted to measure
core body temperature and blood pressure respectively. Temperature, arterial blood
pressure, and heart rate were monitored throughout the surgery.
The experiment contained three animal groups, water-injected, desipramine
treated and control. In the water-injected group, osmotic brain edema was induced
during surgical anesthesia. These animals received an intraperitoneal injection of
distilled water at room temperature equivalent to 15% of the body weight. The second
group received no water injection but was given intraperitoneal injections of desipramine
(10 mg/kg) daily for two weeks prior to induction of surgical anesthesia. In the control
group, animals underwent surgery and were anesthetized similar to the water-injected
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group but were not injected with water. All animals were monitored for two hours under
anesthesia. Blood samples were collected at the beginning of the experiment and at 15,
30, 60, 90 and 120 min after the animal was hemodynamically stable. Blood osmolality
was measured in each blood sample while the hematocrit levels were obtained at the 0
and 120 minute time points. Blood osmolality was measured by a vapor pressure
osmometer (Wescor 5500, Salt Lake City, UT). Hematocrit levels were assessed after
centrifugation (Clay-Adams Micro-Hematocrit, New York City, NY) After 120 min
animals were either perfused with fixative or rapidly decapitated while under anesthesia.
Circulatory perfusion was performed following thoractomy. The right auricle was
severed and a 16 gauge tube was placed through the left cardiac ventricle. Animals were
first exsanguinated by perfusion of 200 ml normal saline followed by 200 ml of 4%
paraformaldehyde in 0.085 M phosphate buffer under a pressure of approximant 1 m of
water at the cardiac ventricle. Other rats were decapitated without circulatory perfusion,
for these animals the brains were removed for analysis of water content and AQP4
expression.
Brain water analysis
After decapitation and rapid dissection from the skull, the brain was divided along
the sagittal fissure. The cortex of one hemisphere was removed from the underlying
brain stem using a stainless steel spatula.
All brain tissues were placed in preweighted porcelain crucibles and weighed to
determine the brain wet weight.

Specimens then were placed in an oven for 48 hours at
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105° C. The crucibles were reweighed to determine the brain dry weight and the percent
total water content was calculated from the formula,
Percent water content = brain wet weight – brain dry weight x 100%
brain wet weight
Four animals from each group were used to determine percent water content.
Tissue extraction and preparation for protein analysis
The cerebral cortex not used for rain water analysis was promptly dissected from
the diencephalon and placed in liquid nitrogen. Samples then were stored at -70°C until
processing. Roughly 70 mg of tissue was homogenized in 1 ml lysis buffer (FNN0071,
Invitrogen, Carlsbad, CA) containing 1 µm dithiothreitol and protease inhibitor cocktail
(P2714, Sigma-Aldrich, St. Louis, MO) using a glass hand homogenizer. The
homogenized samples were allowed to incubate on ice for 10 min prior to a 5 min
centrifugation at 12,000 x g. The protein-containing supernatant lysate then was used for
protein assay using bicinchoninic acid BCA method, and for western and dot blot
analysis. Three day-old neonatal rat liver tissue was used as a negative control and was
processed using the same homogenization and lysis technique.
Protein assay
Ten microliters of each brain lysate were combined with 90 µl of water in 1 ml
BCA solution (Sigma Aldrich, St Louis, MO). Standards and tissue lysates then were
incubated for 25 min at 40°C. Sample optical densities at 560 nm minus that at 650 nm
were analyzed using a Universal Micro Plate Reader (ELx800). The standard protein
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concentration curve using bovine serum albumin was used to determine the total protein
concentration of each lysate sample.
Polyacrylamide gel electrophoresis and membrane transfer
Methods used were modified from Vajda et al and Tomassoni et al [44, 72].
Brain lysate (15 or 30 µg protein) was mixed with 20 µl of Laemmli standard buffer
(161-0737, Biorad, Hercules, CA) containing either β-mercaptoethanol or dithiothreitol
(5%, 10% or 40%). Samples were heated for 9 min at 95° C and loaded onto 10%
precast gels (Mini-Protean 456-1034 Biorad, Hercules, CA). Electrophoresis was run at a
constant 100 V for 80 min. Following electrophoresis, proteins were transferred to
PVDF membranes for 18 hours at 50 mA.
Western blot analysis
Methods were modified from Oliva et al. [114]. Following protein transfer PVDF
membranes were rinsed for 10 min with TTBS consisting of 0.15 M NaCl, 0.02 M TrisHCl, and 0.05% Tween-20, pH 7.5. The membranes then were blocked in 5% non-fat
dry milk (170-904, Biorad Hercules, CA) for one hour followed by 4 five minute washes
in TTBS. Membranes were incubated overnight in primary antibodies for either
aquaporin-4 (1:5000, AB2218, Millipore, Billerica, MA) or β-actin (1:5000, 600-401886, Rockland, Gilbertsville, PA). After overnight exposure, a series of four washes was
done in TTBS followed by one hour incubation in HRP-conjugated secondary (1:25,000,
170-5046, Biorad, Hercules, CA). A final series of rinses was done with TTBS. Blots
were imaged using ECL substrate on a Fujifilm LAS-3000 chemiluminescence imager.
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Dot blot analysis
Nitrocellulose membranes (162-0168, BioRad, Hercules, CA) were submerged in
transfer buffer (25 mM Trizma base, 192 mM glycine and 0.5% sodium dodecyl sulfate)
prior to sample loading. A single membrane was loaded into a vacuum filtration
manifold system with 20 wells (Gibco BRL 11055, Life Technology). An equal amount
of brain protein (50 µg) was loaded into each well of the apparatus and vacuum was
engaged. To serve as positive control 0.5 µg AQP4 control peptide (AQP41-p, Alpha
Diagnostics, San Antonio, Texas) was loaded in some wells. After ten min the vacuum
was removed and the membrane was washed in TTBS. The membrane then was blocked
in 5% non-fat dry milk (170-904, Biorad, Hercules, CA) for one hour followed by 4 five
minute washes in TTBS.
Membranes were incubated for one hour in primary antibodies for either AQP4
(AB2218, Millipore, Billerica MA) or β-actin (600-401-886, Rockland, Gilbertsville,
PA). For one membrane AQP4 primary antibody was pre-absorbed using an equal
amount (by mass) of AQP4 control peptide. After one hour of incubation, a series of four
washes was done in TTBS followed by one hour incubation in HRP-conjugated
secondary (170-5046, Biorad, Hercules, CA). A final series of rinses was done with
TTBS. Blots were imaged using ECL substrate on a Fujifilm LAS-3000
chemiluminescence imager. Band intensity was measured in arbitrary units and was
corrected for the local background by subtraction. A total of 4, 3 and 5 rats were used in
the control, water-injected and desipramine treated animal groups respectively.
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Tissue preparation and cryosectioning for immunohistochemistry
Following perfusion fixation of the animal, the calvaria was carefully removed to
expose the brain. The brain was dissected from the skull and placed in 4%
paraformaldehyde in 0.095 M phosphate buffer for two hours. After 2 five minute rinses
in phosphate-buffered saline (PBS) the brains were stored in PBS containing in 30%
sucrose at 4° C until cryosectioning.
Prior to cryosectioning the tissue was transferred to 1:1 mixture of PBS and tissue
embedding media (SH75-125D, HistoPrep TM) for 30 min. Then, the tissue was fully
submerged in the embedding media. Brains were sectioned coronally at 20 µm in the
mid-frontal region. Brain sections were mounted on glass slides and stored at -70° C
until staining.
Immunohistochemical staining
Modified methods from Tomassoni et al were used [72]. Slides from each
treatment group were stained on the same day. Slides containing 20 µm brain sections
were washed in a PBS-T solution consisting in 1% Triton X-100, 1 M Na2HPO4, 144 mM
NaCl pH 7.42. Following 2 five min rinses the sections were soaked in a PBS-T
containing 1% paraformaldehyde for 30 min. Sections were rinsed in PBS-T and then
soaked for 30 min in PBS-T containing 1 mg/ml sodium metaborate (10555-76-7, Sigma
Aldrich, St. Louis, MO) to decrease autofluorescence. A third series of rinses was
performed with PBS-T and the sections were soaked in 20% normal goat serum (005000-121, Jackson Immuno Research, West Grove, PA) for 15 min. The sections were
incubated with primary antibodies at 4°C overnight. Three primary antibodies were used
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for immunohistochemistry; mouse anti-glial fibrillary acidic protein (1:750, SMI-22,
Covance, Lutherville, MD), mouse anti-blood brain barrier protein (1:1000, SMI-71,
Covance, Lutherville, MD) and rabbit anti-aquaporin-4 (1:500, AQP41-S, Alpha
Diagnostic, San Antonio, Texas). The next day the slides were rinsed and probed with a
secondary antibody conjugated with a fluorescent molecule. Either Alexia Fluor 555
(1:500 Invitrogen) or FITC (1:100, 111-095-144, Jackson Immuno Research, West
Grove, PA) was used to visualize the anti-AQP4 antibody while FITC (1:100, 115-095062, Jackson Immuno Research, West Grove, PA) was used to visualize anti-blood-brain
barrier and anti-GFAP antibodies. A final rinse with PBS-T to remove unbound
antibodies was completed followed by a deionized water wash. Sections were preserved
in mounting media (17985-10, Electron Microscopy Sciences) with an overlying cover
slip. Images were acquired using both laser confocal and epifluorescence microscopy.
Epifluorescence and confocal laser microscopy
Fluorescence microscopy was used to determine the location of AQP4, the SMI71 blood-brain barrier associated protein and GFAP in the brain.

Epifluorescence

images were captured using Olympus BX51 and Nikon Eclipse E600 microscopes.
Images were analyzed using Image J 1.37C. Confocal microscopy was performed using
a Nikon Eclipse C1 Plus system containing three lasers to determine the
immunoreactivity of AQP4 at the glial endfeet surrounding capillaries. Laser lines of 488
nm (for FITC) and 561 nm (for Alexa Fluor) were used to excite the fluorescent labeled
antibodies. A photo-multiplier detector (PMT) was used to detect fluorescence emission
at 450 ± 25 nm, 525 ± 25 nm, and 595 ± 25 nm. NIS Elements Advanced Research 3.20
software was used to analyze images.
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A structured method to analyze AQP4 localization was employed (Fig 3). In
each section four regions of interest (ROI) were selected in the cerebral cortex near the
saggital fissure. A z-stack of roughly sixty images separated by 0.2 µm was acquired.
The image in each z-stack containing the highest mean intensity of immunoreactivity was
selected for analysis. At the selected z-plane, the four strongest stained capillaries cut in
cross section were analyzed using a linear intensity profile. The resulting histogram of
pixel intensities was evaluated by determining the maximum pixel intensity and
normalizing this value to the average intensity of five pixels in the adjacent background
(Figure 3D). Four 20 µm sections were analyzed for each animal. Thus, intensity profiles
of 48-64 capillaries were recorded for each animal. Each animal’s average intensity
profile was then average within the treatment group. These normalized intensities were
then averaged to give a single measure of relative AQP4 immunofluorescence for each
animal. Three animals from each group were used for immunohistochemistry.
Statistical analysis
Significance was considered for p values lower than 0.05. Repeated measure
ANOVA with post-hoc Dunnett’s test was used to evaluate changes in blood osmolality.
Student’s t-test was done to evaluate changes in brain water content. Independent
Student’s t-tests were used to compare each treatment group to controls for analysis of
initial plasma osmolality, hematocrit, heart rate, blood pressure and temperature.
ANOVA single factor analysis at (alpha 0.05) was used for the analysis of initial
hematocrit and osmolality between groups. To compare ratios of maximal intensity to
background average during confocal laser analysis, Mann-Whitney U-test was

47

performed. Mann-Whitney U-test was also used for dot blot analysis of total aquaporin 4
protein. Data are reported as mean ± standard error mean (SEM).
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Figure 3. Example of confocal laser fluorescence intensity of a coronal section in rat
brain. For each coronal section, four regions of interest (ROI) (A) were selected and zstacks of images were acquired with an image spacing of 0.2 µm (B). The image plane
with the highest mean intensity was selected for measurements (B) to evaluate the
localization of AQP4 immunoreactivity. Four capillaries were analyzed in each selected
z-plane (C). Localization of AQP4 was quantified by calculating the ratio of the
maximum intensity relative to the average intensity of pixels in the adjacent neuropil (D).
Pixel intensity is measured in arbitrary units (AU) and sequential pixels along the line
going through each capillary are expressed on the horizontal axis (D). Each pixel
corresponds to 0.41 µm.
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CHAPTER V
RESULTS
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Blood pressure, heart rate and core temperature
Each animal’s heart rate, temperature and blood pressure were recorded
throughout anesthesia. Initial (t= 0 min), 15 min and final (t= 120 min) values are
summarized in Tables 2 and 3. Initial values were not significantly between treatment
groups for any of these parameters (Heart Rate F=0.569, P=0.57; Core Temp F= 2.204
P=0.13; Systolic Pressure F=0.233 P=0.79; Diastolic Pressure F= 2.28 P= 0.12).
A significant decrease in heart rate was observed in water-injected animals 15 min
and two hours after water injection. A significant core body temperature decrease also
was observed 15 min after water injection. In water-treated animals a significant increase
in systolic and diastolic pressure was observed at the 2 hour time point, but not 15 min
after water injection.
Animals treated with desipramine had significantly elevated diastolic pressures at
all time points compared to controls. Diastolic pressures did not change during the two
hour anesthesia within either the control or desipramine group. At the two hour time
point, these drug-treated animals also showed a decrease in core temperature compared to
the initial measurement.
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Table 2. Heart rate and core temperature values are the mean ± SEM from 7-12 animals
measured at initial (t = 0), 15 min (t = 15) and final (t = 120 min) time points. For
animals receiving IP water injection, 15 minute values are 15 min after the injection. *
indicates significance against initial values.

53

Control
Water Injected
Desipramine

Heart Rate
Beats Per Minute ± SEM
0 min
15 min
120 min
392 ± 10 388 ± 9
379 ± 8
379 ± 8
334 ±13* 350 ± 9*
386 ± 6
390 ± 5
375 ± 7
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Core Temperature °C ± SEM
0 min
15 min
120 min
37.5 ± 0.2 37.6 ± 0.2 37.4 ± 0.2
37.8 ± 0.2 35.6 ±0.2* 37. 6 ± 0.2
37.4 ± 0.1 37.4 ± 0.1 37.0 ±0.1*

Table 3. Arterial systolic and diastolic pressure values are the mean ± SEM from 7-12
animals measured at initial (t = 0), 15 min (t=15) and final (t = 120 min) time points. *
indicates a significance difference compared to the initial values. ◊ indicates a
significance difference compared with controls.
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Control
Water Injected
Desipramine

Arterial Systolic
(mm Hg ± SEM)
0 min
15 min
120 min
103 ± 6 97 ± 6
91.4 ± 4
106 ± 7 110 ± 4 123 ± 7*
107 ± 3 107 ± 4 103 ± 3
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Arterial Diastolic
(mm Hg ± SEM)
0 min
15 min
120 min
63 ± 4
60 ± 4
53 ± 5
68 ± 4
75 ± 4
80 ± 5*
◊
◊
73 ± 3
73 ± 3
68 ± 2◊

Blood plasma osmolality
Figure 4 shows blood plasma osmolality while animals were under anesthesia.
Beginning osmolalities (measured at t = -20 min) were similar in each treatment group
(F=0.340, p= 0.67). The overall average osmolality of all animals was 295 ± 1 mOsm.
Relative to the initial value, osmolality decreased significantly in the water injection
group 15, 30, 60, 90 and 120 min after intraperitoneal injection (t = 0). Blood osmolality
dropped drastically during the first thirty min after IP injection and appeared to stabilize
to a constant value thereafter. Plasma osmolality of control and desipramine groups
showed no significant difference throughout the study period.
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Figure 4. Blood plasma osmolality of control and treatment groups during anesthesia.
Time -20 min indicates the time immediately after femoral catheter insertion. At time
zero animals in the water injection group received an intraperitoneal water injection. *
indicate significance difference relative to controls.
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Figure 5. Blood was collected for hematocrit analysis immediately following femoral
artery catheterization (initial) and at the termination of the experiment approximately two
hours later (final). Relative packed cell volume is shown on the Y axis. Error bars
indicate standard error. * indicate significances difference relative to the initial values.
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Hematocrit analysis
The hematocrit of arterial blood was measured in animals from all three groups
immediately after the initial insertion of the arterial catheter and at the termination of the
experiment (Figure 5). ANOVA analysis of the initial hematocrit value between the three
groups showed no significance (F=0.466, p=0.63). The control group showed a
significant decrease (8.4% ±1.8) in hematocrit during the experiment. Water injected
animals had a significant increase (11.0% ± 1.7) in packed cell volume. The plasma in
the water injected animals was also red in color for the final determination. No
difference was seen in the desipramine group.
Cortical brain water content
Control animals had 79.8 ± 0.2 %water in cerebral cortical brain tissue (Table 4).
The water-injected animals showed a significant increase in cortical brain water content,
to 81.3 ± 0.1 % water. No difference in brain water content (79.2 ± 0.4 %) was noted in
the drug-treated animals compared to control animals.
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Table 4. Cortical brain tissue water content of the three rat groups. Water content was
determined by ((brain wet weight – brain dry weight) / (brain wet weight)) x 100%. *
indicates significant difference compared with control animals.
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Groups
Control
Water Injected
Desipramine

Brain Water Content
% ± SE
79.8 ± 0.2
81.3 ± 0.5*
79.2 ± 0.4
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N
4
4
5

Aquaporin 4 epifluorescence immunohistochemistry
Coronal sections from the mid-frontal regions were used to investigate AQP4
localization in the rat brain. Strong signal intensities for AQP4 immunoreactivity were
seen along endothelial cells throughout the cerebral cortex as indicated by colocalization
of immunoreactivity for the blood brain barrier (SMI-71) and AQP4 markers (Figure 6).
In capillaries AQP4 appeared to be superimposed on the SMI-71 antibody. In larger
vessels however, a clear distinction can be made between AQP4 and SMI-71 localization
with AQP4 surrounding the blood vessels endothelial layer. In contrast, AQP4
immunoreactivity was colocalized with glial fibrillary acid protein immunoreactivity near
blood vessels (Figure 7. Strong AQP4 staining also was observed at the glial limitans
(Figure 7) and near the ependymal cells of the choroid plexus.
Aquaporin 4 distribution at astrocyte endfeet
Three rats were used in each group and 48-64 capillaries were measured per rat
(Figure 8). Relative to background staining, the intensity of AQP4 immunoreactivity
increased significantly in both the water-injected and desipramine treated groups, when
compared to the controls (Table 5). Water injected animals show a 24% increase in
AQP4 relative immunofluorescence compared to controls. Desipramine treated animals
show a 13% increase in signal ratio compared to controls.
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Figure 6. AQP4 epifluorescence (right) and SMI-71 epifluorescence (left) in each
treatment group.
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Figure 7. Epifluorescence of AQP4 immunoreactivity around a cerebral vessel (top left,
and at glial limitans (bottom). GFAP immunoreactivity around cerebral vessel (top right).
Top images were taken at the same location.
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Table 5. Peri-capillary aquaporin 4 signal strength recorded with quantitative confocal
microscopy. The signal intensity represents the ratio between the maximum intensity at a
capillary wall relative to the background. * indicates significant difference compared
with control animals.
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Control
Water Injected
Desipramine

Signal Intensity ± SE
2.6 ± 0.04
3.2 ± 0.21*
3.0 ± 0.13*
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N
3
3
3

Figure 8. Aquaporin intensity profile through a cerebral vessel. The histogram
corresponds to pixel intensity along the blue arrow seen on the confocal laser micrograph.
The ratio of the maximal signal to the average of five pixels in the background was
compared between each treatment group. AU indicates arbitrary units used to measure
pixel intensity. Each pixel corresponds to 0.41 µm.
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Aquaporin 4 Histogram
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Aquaporin 4 expression
Western blot analysis of brain lysate showed a single band when probed for to βactin (Figure 9A). Immunoreactivity of AQP4 showed several bands between 25-75 kD,
with intense staining at higher molecular weights. Sample buffer containing 5% βmercaptoethanol (1x BME) was used for these initial investigations (Figure 9 A and B).
In an attempt to increase AQP4 stain in a single distinct band at the expected molecular
weight increased concentration of reducing agents were used. Concentrations of BME
equal to 2 or 4 times normal did not appreciably change appearance of the AQP4 western
blot (Figure 9 A1-3). Replacing BME with 1M dithiothreitol (1x DTT) also resulted in a
spread of high molecular weight with no distinct band at lower molecular weights.
Increasing the concentration of either reducing agent caused higher molecular weight
staining, and a decrease in banding at the expected value. An 8 fold increase in BME
(C3) eliminated almost all banding below ~100kDal and produced single high molecular
weight band. In addition to altering reducing agent concentration several other variables
were altered in order to attempt to observe a band at the expected level. Changes in the
lysis buffers, heating techniques, transfer time, transfer voltage, antibody incubation
length, and varying concentration of antibodies were performed. A distinct band at the
expected weight was not observed using any of these alterations.
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Figure 9. Western blots probed for AQP4 and β-actin. Membrane A corresponds to βactin immunoreactivity in 15 µg (Lane 1) and 30 µg (Lane 2) of brain lysate. Membrane
B and C correspond to AQP4 immunoreactivity in 15 µg (Lane B1) and 30 µg (Lane B2:
C1-C7) of brain lysate. Lysates probed in membrane C were treated with one of two
reducing agents (DTT and β-mercaptoethanol (BME)) at various concentrations C1:
355mM BME, C2: 750 mM BME, C3: 2840 mM BME, C4: 50 mM DTT, C5: 100mM
DTT, C6: 400mM DTT, C7: no reducing buffer.
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Protein quantification using dot blot method
An initial analysis was performed to determine the relation between AQP4
immunoreactivity and quantitity of brain lysate added to dot blot wells. Various
quantities of brain lysate from a control animal was loaded into each well. The resulting
pixel intensity showed a linear increase with the total amount of control brain lysate
between 11 µg and 88 µg (Figure 10).
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Figure 10. Control rat brain lysate probed for AQP4 using different amounts of control
brain lysate in each well. AU represents arbitrary units used to compare pixel intensity.
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Aquaporin 4 antibody binding specificity
Preabsorbing the AQP4 primary antibody with an AQP4 control peptide produced
a decrease in pixel intensity in two control brain lysate samples (10 µg and 40 µg) (Figure
G). Neonatal liver and bovine serum albumin served as a negative control and showed
minimal intensity when probed for AQP4. Aquaporin 4 control peptide and brain lysate
were loaded as positive controls (Figure 11).
Aquaporin 4 expression following water injection and desipramine treatment
Cerebral cortical aquaporin 4 content determined with dot blot analysis did not
change significantly across the three treatment groups (F=0.403, P=0.68). There was a
wide variability of the raw data within each treatment group: control (23.5 AU ± 8.7),
water injected (29.2 AU ± 10.2) and desipramine (25.4 AU ± 6.5). Similar coefficients of
variability also were seen within each group when β-actin immunoreactivity was
analyzed: control (5.6 AU ± 0.40), water injected (8.0 AU ± 1.6) and desipramine (5.2 ±
1.2). However, β-actin immunoreactivity showed a significant increase in the water
treatment group compared to controls. The ratio of AQP4 immunoreactivity relative to βactin immunoreactivity showed no significance across the three animal groups (F=0.787,
P=0.49). However, normalizing AQP4 immunoreactivity data to β-actin decreased the
coefficient of variation compared to un-normalized AQP4 immunoreactivity. Normalized
data are summarized in Table 6.
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Figure 11. Specificity of aquaporin 4 antibody dot blot analysis. Preabsorption of
primary antibody with a 17 amino acid c-terminus AQP4 control peptide (A). Two
protein amounts were loaded on a vacuum dot blot aparatus. The intensity of each well
probed with native or preabsorbed antibody is shown in B. Liver, bovine albumin, brain
lysate and AQP4 control peptide (AQP-CP) were loaded and probed for AQP4 in C.
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Table 6. Aquaporin 4 immunoreactivity normalized to β-actin using dot blot analysis
technique. No significant difference was found between the groups.
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Control
Water
Injected
Desipramine

AQP4
immunoreactivity
normalized to β-actin
(AU)
4.25

Standard
Error
0.85

N
4

3.77
4.91

0.90
0.28

3
5
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CHAPTER VI
DISCUSSION
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Aquaporin 4 localization and expression response to osmotic brain edema
A successful induction of osmotic brain edema was confirmed by changes in
serum osmolality and brain water content. While water injection also caused a significant
decrease of the core temperature after fifteen min the animals recovered to normal body
temperature within two hours. Consistent with previous studies [44, 47, 69, 70, 107],
blood plasma osmolality showed a significant drop from 294 ± 2.5 mOsm to 277 ± 1.3
mOsm 15 min after the intraperitoneal water injection. After the initial drop observed at t
= 15 min, blood osmolality remained relatively stable throughout the remaining two hour
study. A significant increase in hematocrit of water injected animals also provides
evidence for systemic hypotonicity. As absorption of water into the mesenteric
vasculature reduces the tonicity of the plasma, an osmotic gradient would move water
into the erythrocytes. The increase observed in the packed cell volume is evidence of this
swelling. Additionally, after water intoxication the plasma fraction contained some red
color, evidence of erythrolysis.

Interestingly, the control animals showed a slight, but

significant, decrease in a hematocrit. This decrease is probably a result of repetitive
blood sampling with liquid replacement. After each blood extraction an equal amount of
normalized saline was injected into the animal to maintain patency of the arterial line.
This may have reduced the number of circulating blood cells and diluted those which
remain.
Consistent with several other publications regarding osmotic brain edema [46, 60,
69, 70, 81], brain water content showed a significant increase in water-injected animals.
It is suspected that systemic hyposmolarity caused an efflux of water from the lumen of
the capillaries into the brain interstitial space. To determine the role AQP4 plays during
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influx of water into the brain parenchyma, immunohistochemistry was performed on
control and water-treated rats. In both groups we observed strong AQP4 localization at
astrocytic endfeet surrounding capillaries. This AQP4 immunoreactivity at the astrocytic
endfeet was increased in water-treated animals. Similar findings of increased AQP4
immunoreactivity during 1.5 and 4 hours of osmotic brain edema have been reported
elsewhere [44, 46].
Analysis of AQP4 expression using western blot analysis proved ineffective. We
observed immunoreactivity to the AQP4 antibody at high molecular weights together
with one band near the reported AQP4 molecular weight of 34 kDa (Figure 9B). Similar
outcomes were observed using a variety of cell lysis kits (MCL-1 Sigma Aldrich;
FractionPREP, Biovision) containing various detergents, reducing agents, and
concentrations of primary and secondary antibodies. We suggest that the higher weight
immunostaining is a result of AQP4 oligomers that do not separate in the lysis process
nor dissociate during electrophoresis. The inability to quantify the results using western
blot analysis prompted a different approach. A 1D dot blot method was used. We
demonstrated that dot blot analysis can be used to quantitatively measure AQP4 content
by; 1) showing an increase of immunoreactivity with an increase of total protein (Figure
10), 2) showing negative AQP4 immunoreactivity for bovine serum albumin and neonatal
liver, and 3) showing a decrease in AQP4 immunoreactivity when probed with AQP4
antibody that had been preabsorbed with AQP4 antigen peptide (Figure 11). Unlike
previous findings [44] we did not observe any differences in AQP4 expression during
osmotic brain edema. There could be several explanations for this different result. First,
in one previous study Vajda et al. [44] measured AQP4 expression at 4 and 48 hours,
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while we measured at two hours, a time where BBB water permeability has decreased
[44, 70]. Secondly previous studies analyzed only bands near the reported weight, while
we measured all AQP4 immunoreactivity using dot blot analysis. Interestingly, others
reported that AQP4 mRNA expression also is unaltered during 4 and 48 hour osmotic
brain edema [44].
The increase in AQP4 localization at astroglial endfeet using
immunohistochemistry but no increase in total AQP4 expression using dot blot analysis
suggests that either; 1) there was an increase in availability AQP4 polarized to the endfeet
by protein redistribution or 2) A conformational change at the c-terminus of AQP4 during
osmotic brain edema results in a higher affinity of antibody to epitope. In summary the
analysis of AQP4 suggests that the increase in AQP4 immunoreactivity at the astrocytic
endfeet is not a result of increased total AQP4 protein in the brain but possibly
redistribution of AQP4 along the astrocytic membrane. Thus any AQP4 alterations in
response to systemic hyponatremia are a result of post transcriptional factors.
Aquaporin 4 localization and expression response following chronic treatment of
desipramine
Our goal in the second part of the project is to determine if a tricyclic
antidepressant (TCA), which has been shown to increase BBB water permeability in the
brain [106, 113], would alter AQP4 expression and distribution. Modification of brain
catecholamines has been shown to affect BBB transport of water [13, 14]. Desipramine
was chosen from other TCAs because of its selective effect on the noradrenergic system.
Desipramine and other secondary amine TCAs show a higher potency to inhibit
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norepinephrine reuptake compared to tertiary amine TCAs [115, 116]. In addition, a
previous study using quantitative autoradiography shows desipramine’s high binding
affinity to norepinephrine terminals [117].
Animals receiving daily treatments of desipramine for 14 days had similar heart
rates, systolic blood pressures and core temperatures compared with untreated controls.
However diastolic blood pressure was elevated significantly compared to controls. This
elevation in diastolic blood pressure is also observed in humans undergoing TCA
treatment [118]. Blood osmolality and hematocrit of desipramine-treated animals
showed no significant difference compared to controls. The general location of AQP4
immunostaining also was unchanged between the two groups, showing strong staining at
both astrocytic endfeet and at the glial limitans. Quantitative analysis of AQP4
immunostaining intensity at astroglial endfeet however, showed a significant elevation in
the desipramine group compared to controls. The increase in AQP4 immunostaining at
the endfeet was not reflected in AQP4 findings using dot blot analysis. Thus, our
findings suggest that the AQP4 signal increase at the astroglial endfeet is not a result of
an increase in global protein expression but instead a possible redistribution along the
astrocytic membrane. Increased immunostaining at the endfeet however could also be a
result of a change in AQP4 c-terminus conformation during treatment. The findings that
AQP4 redistribution occurs toward the glial endfeet is consistent with the increase in
water permeability in the brain seen after desipramine treatment [113]. To our
knowledge this is the first study showing evidence of an increase in AQP4
immunostaining at astrocytic endfeet during chronic TCA treatment. Since desipramine
selectively inhibits norepinephrine reuptake [119], we suggest that the noradrenergic
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system either directly or indirectly regulates AQP4 distribution. This connection of the
noradrenergic system regulating AQP4 expression has been suggested elsewhere [120].
It has been shown previously that stimulation of the locus coeruleus in the monkey
increases water permeability in the brain [13], but it is unclear if this increase in water
permeability is from a distribution of AQP4 or stimulation of AQP4 activity.
In conclusion we have examined AQP4 distribution and expression using two
models, which have been shown to alter water permeability in the brain. Interestingly,
each of these models show opposite effects in cerebral water permeability. We suggest
that the increase of AQP4 immunostaining in desipramine-treated animals is a reflection
of an increase of AQP4 at the astrocytic endfeet from redistribution and not from an
increase of total AQP4 protein expression in the brain. In contrast, the down regulation
of water permeability in water-injected animals observed previously is not due to a
redistribution of AQP4 away from the astrocytic endfeet. Instead alterations in AQP4
activity must play an important role in regulating water permeability in this model of
cytotoxic brain edema.
Limitations and future directions
Our study has several limitations. Our immunohistological studies were
structured to evaluate AQP4 staining in the cerebral cortex. Cerebral cortex was selected
because it has been shown to have a higher density of capillaries compared to white
matter [121]. Our results showing an increase in AQP4 signaling at the astrocytic endfeet
should not be used to address the global distribution of AQP4 in the brain. Additionally,
our primary antibody was selective to the c-terminus of AQP4. Changes in c-terminus
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configuration making the epitope more accessible to the antibody is a potential cause for
the observed increase in AQP4 immunoreactivity at astroglial endfeet. Additional
antibodies directed to the n-terminus or another location should be used to confirm these
results. However, care should be taken when choosing n-terminus antibodies because of
differences between the three isoforms of AQP4 are at the n-terminus. In order to firmly
establish the possible redistribution of AQP4 during these treatments, freeze fracturing
technique may be used.
Western blot analysis was show to be ineffective using our methodology. Most
publications do not show entire blots of AQP4 probed membranes to determine if
multiple oligomers are present. Several sources have suggested dimers and tetramers of
AQP4 are present in westerns blots; however, few have measured these. Measuring all
bands to determine total AQP4 protein expression may be the best method to determine
AQP4 protein content in the brain. Our results showed a large coefficient of variation
using 3-5 animals per group. An increase in power may decrease this variability.
Aquaporin 4 regulation mechanisms and their role in water transport in the brain are still
largely understudied. Additional studies regarding protein expression, localization, and
structural modification of AQP4 should be performed in order to determine this
mechanism regulating blood-brain barrier water permeability and devise therapeutic
agents to assist in clinical pathology remedies.
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